Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The Company intends to use the net proceeds from the transaction for its ongoing clinical and regulatory development of Lomecel-B™ for the treatment of several disease states and indications, including HLHS and Alzheimer's disease, obtaining regulatory approvals, capital expenditures, working capital and other general corporate purposes. This press release does not constitute an offer to sell or a solicitation of an offer to buy ...